• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lumos Pharma Inc (NQ: LUMO )

    4.335 +0.015 (+0.35%)
    Streaming Delayed Price Updated: 12:05 PM EST, Nov 19, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 37,612
    Open 4.320
    Bid (Size) 4.330 (3)
    Ask (Size) 4.340 (1)
    Prev. Close 4.320
    Today's Range 4.320 - 4.350
    52wk Range 1.370 - 4.576
    Shares Outstanding 8,357,391
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, OB on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates LUMO, PIK, INSI on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire

    Performance

    YTD
    +34.63%
    +34.63%
    1 Month
    +16.22%
    +16.22%
    3 Month
    +44.02%
    +44.02%
    6 Month
    +65.46%
    +65.46%
    1 Year
    +41.67%
    +41.67%

    More News

    Read More
    Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Analyst Expectations For Lumos Pharma's Future
    Via Benzinga
    Lumos Pharma: Q4 Earnings Insights
    Via Benzinga
    INVESTIGATION ALERT: Halper Sadeh LLC Continues to Investigate MMLP, FSHP, ICCH, and LUMO on Behalf of Shareholders
    From Halper Sadeh LLC
    Via GlobeNewswire
    LUMO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Lumos Pharma, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Shareholder Alert: Ademi LLP Investigates Whether Lumos Pharma, Inc. Is Obtaining a Fair Price for Its Public Shareholders
    From Ademi LLP
    Via Business Wire
    Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    LUMO Stock Earnings: Lumos Pharma Misses EPS for Q4 2023
    Via InvestorPlace
    Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
    From Lumos Pharma, Inc.
    Via GlobeNewswire
    Earnings Scheduled For March 7, 2024
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.